PDE5A and pulmonary arterial hypertension: In a small cohort study, PAH-targeted therapies-including endothelin receptor antagonists, phosphodiesterase-5 (PDE5) inhibitors, and prostacyclin analogs-have been associated with improvements in mPAP, PVR, and NYHA functional class in NF1-associated PAH [3].